Bruce Booth Sells Shares of Kymera Therapeutics
Bruce Booth sold 278,128 shares of Kymera Therapeutics, Inc., in a planned sale.
Key Points
- Bruce Booth sold 278,128 shares of Kymera Therapeutics, Inc. on June 22, 2026, with the shares valued at approximately $27.57 million.
- Kymera Therapeutics has a market cap of $8.18 billion, a forward P/E of -22.89, and a 52-week range between $36.65 and $105.00.
- Recent analyst ratings for Kymera Therapeutics include several 'buy' ratings with price targets as high as $140.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Bruce Booth, an insider at Kymera Therapeutics, Inc. (NasdaqGM: KYMR), sold 278,128 shares on June 22, 2026. This planned sale was executed at an average price of $99.12 per share, totaling approximately $27.57 million.
Insider Buying and Selling at Kymera Therapeutics, Inc.
On June 22, 2026, Bruce Booth sold 278,128 shares of Kymera Therapeutics in a planned transaction. Additionally, Noah Goodman, Chief Business Officer, sold 2,500 shares at $99.00 per share in a planned sale and bought 2,500 shares at $21.05 in an unplanned transaction on the same day.
Other Institutional Activity in Kymera Therapeutics
FMR LLC increased its holdings in Kymera Therapeutics by 2,771,376 shares, ending with 11,699,950 shares worth about $974.49 million. T. Rowe Price Investment Management, Inc. significantly boosted its position by 4,835,252 shares, bringing its total to 5,464,997 shares valued at approximately $455.18 million. Meanwhile, Price T Rowe Associates Inc /MD/ trimmed its stake by 98,488 shares to hold 6,060,847 shares worth $504.81 million.
Kymera Therapeutics, Inc. Stock Down 15.8%
Shares of NasdaqGM:KYMR traded near $99.45 on Tuesday. Kymera Therapeutics, Inc. has a market capitalization of $8.18 billion and a forward P/E ratio of -22.89, indicating the company is not yet profitable. The stock has experienced a 52-week low of $36.65 and a high of $105.00, with a 50-day moving average of $83.06 and a 200-day moving average of $73.55. The company maintains a strong balance sheet with a current ratio of 10.81 and a quick ratio of 10.39, alongside a debt-to-equity ratio of 5.23.
$KYMR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Recent analyst activity includes Canaccord Genuity initiating coverage with a 'buy' rating and a price target of $106.00 on May 6, 2026. UBS maintained its 'buy' rating with a target of $128.00 on March 3, 2026. Piper Sandler and BTIG both maintained 'buy' ratings with high targets of $140.00 and $138.00, respectively, earlier in 2026. The overall consensus from 21 analysts is a 'strong buy,' with a mean price target of $119.19.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing small molecule therapeutics that target and degrade disease-causing proteins. The company's pipeline includes KT-621 for treating inflammatory conditions and KT-579 for autoimmune diseases. Kymera also collaborates with Sanofi S.A. on drug candidates targeting IRAK4. Founded in 2015, Kymera is led by CEO Dr. Nello Mainolfi and employs 253 people.
Bottom Line
Insider transactions like Bruce Booth's planned sale are closely watched by investors for potential insights into company performance. Kymera Therapeutics' stock remains volatile with a wide 52-week range, reflecting both growth potential and market uncertainty. Analysts' strong buy ratings and high price targets suggest confidence in the company's future developments.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.